Cathy Zhuang

Dr. Leong

BIOS 520 Clinical Trials Methodology

20 January 2023

Homework 2

**Why do you think FDA is approving drugs based on surrogate endpoints?**

The FDA may be approving drugs based on surrogate endpoints to offer the treatment availability to patients who have exhausted all their other options. Since surrogate endpoints usually can accelerate clinical trials (in that a surrogate endpoint may present earlier), surrogate endpoints may allow the drug to be on the market earlier and available for patients earlier. This would allow patients the option to possibly be treated earlier with the new drug.

**Do you agree (Yes/No). Why or why not?**

While I think that overall, there are still many issues with using surrogate endpoints, I think that if there is no current treatment for a disease, and if the drug has no glaring SAEs, I agree. In my opinion, having a treatment that may or may not be effective is better than not having any treatment options at all. The only caveat would be that we wouldn’t know about any long-term AEs or SAEs. However, in the short term, if there are no other treatment options available, I would still approve a drug based on surrogate endpoints.